Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/26/24
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/26/24
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous UrticariaGlobeNewsWire • 02/24/24
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 02/06/24
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024GlobeNewsWire • 02/05/24
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/27/23
Celldex: Mast Cell Disease Targeting Continues To Make Advancements In ClinicSeeking Alpha • 11/08/23
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, SanofiInvestors Business Daily • 11/06/23
Celldex Therapeutics shares surge as lead asset shows promise in two skin conditionsMarket Watch • 11/06/23
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous UrticariaGlobeNewsWire • 11/06/23
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg BarzolvolimabGlobeNewsWire • 11/05/23
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/02/23
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023GlobeNewsWire • 09/26/23
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/08/23
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/23
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous UrticariaGlobeNewsWire • 07/11/23
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic EsophagitisGlobeNewsWire • 07/06/23
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023GlobeNewsWire • 06/10/23